Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Selution SLR (Sirolimus drug-eluting balloon) completion of patient enrollment in the SAVE Clinical Trial in patients with failed AVF (arteriovenous fistulas) in renal dialysis patients.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SELUTION SLR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
SELUTION SLR (Sirolimus drug-eluting balloon) completion of patient enrollment in the SAVE Clinical Trial in patients with failed AVF (arteriovenous fistulas) in renal dialysis patients.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SELUTION SLR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
SELUTION SLR 018 DEB (Sirolimus drug-eluting balloon) completion of patient enrollment in the SAVE Clinical Trial in patients with failed AVF (arteriovenous fistulas) in renal dialysis patients.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SELUTION SLR 018 DEB
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Sirolimus Release) drug-eluting balloon for the treatment of coronary artery disease.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Selution SLR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cordis
Deal Size: $1,135.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 18, 2022
Details:
The aim of the SELUTION4BTK clinical trial is to demonstrate the superior efficacy and equivalent safety of SELUTION SLR (sirolimus) compared to plain (uncoated) balloon angioplasty (POBA) in the treatment of BTK arteries in CLTI (Chronic Limb Threatening Ischemia) patients.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Selution SLR
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
The objective of this trial is to evaluate the safety and efficacy of the SELUTION SLR DEB in the treatment of infra-inguinal occlusive lesions (TASC C and D) in patients with chronic limb threatening ischemia in 75 patients over 12 months at Singapore General Hospital.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Selution SLR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2021